Author Index

Search or browse for an author across our entire electronic archive

Search results for: L
Results 1 - 10 of 1413 shown below

  • Lænkholm, A-V

    S Hansen, J Overgaard, C Rose, Ann Knoop, A-V Lænkholm, J Andersen, F B Sørensen and P A Andreasen

    Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients

    doi:10.1038/sj.bjc.6600662

  • Läärä, E

    J T Korpi, V Kervinen, H Mäklin, A Väänänen, M Lahtinen, E Läärä, A Ristimäki, G Thomas, M Ylipalosaari, P Åström, C Lopez-Otin, T Sorsa, S Kantola, E Pirilä and T Salo

    Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer

    advance online publication, 2008-02-05 00:00:00.000;

    doi:10.1038/sj.bjc.6604239

  • Léger, F

    F Léger, W J Loos, J Fourcade, R Bugat, M Goffinet, R H J Mathijssen, J Verweij, A Sparreboom and E Chatelut

    Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

    doi:10.1038/sj.bjc.6601469

  • Lépicier, P

    M C Filion, P Lépicier, A Morales and N C Phillips

    Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

    doi:10.1038/sj.bjc.6690038

  • Lévi, F

    T G Granda, R-M D'Attino, E Filipski, P Vrignaud, C Garufi, E Terzoli, M-C Bissery and F Lévi

    Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

    doi:10.1038/sj.bjc.6600168

  • X M Li, K Tanaka, J Sun, E Filipski, L Kayitalire, C Focan and F Lévi

    Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin

    advance online publication, 2005-04-19 00:00:00.000;

    doi:10.1038/sj.bjc.6602564

  • M A Bensmaïne, M Marty, A de Gramont, S Brienza, F Lévi, M Ducreux, E François, E Gamelin, H Bleiberg and E Cvitkovic

    Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) plusminus folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

    doi:10.1054/bjoc.2001.1953

  • Lévy, C

    N Soufir, B Bressac-de Paillerets, L Desjardins, C Lévy, J Bombled, I Gorin, P Schlienger and D Stoppa-Lyonnet

    Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes

    doi:10.1054/bjoc.1999.1005

  • Lévy, P

    F Maire, S Micard, P Hammel, H Voitot, P Lévy, P-H Cugnenc, P Ruszniewski and P Laurent Puig

    Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA

    doi:10.1038/sj.bjc.6600475

  • F Marrache, M P Vullierme, C Roy, Y El Assoued, A Couvelard, D O'Toole, E Mitry, O Hentic, P Hammel, P Lévy, P Ravaud, P Rougier and P Ruszniewski

    Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

    advance online publication, 2006-12-12 00:00:00.000;

    doi:10.1038/sj.bjc.6603526

  • Lévy, V

    V Lévy, S Zohar, C Bardin, A Vekhoff, D Chaoui, B Rio, O Legrand, S Sentenac, P Rousselot, E Raffoux, F Chast, S Chevret and J P Marie

    A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

    advance online publication, 2006-07-18 00:00:00.000;

    doi:10.1038/sj.bjc.6603265

  • Lê, M G

    C Rubino, F de Vathaire, A Shamsaldin, M Labbe and M G Lê

    Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment

    doi:10.1038/sj.bjc.6601138

  • López, J A

    A Pinzon-Charry, C S K Ho, T Maxwell, M A McGuckin, C Schmidt, C Furnival, C M Pyke and J A López

    Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer

    advance online publication, 2007-10-09 00:00:00.000;

    doi:10.1038/sj.bjc.6604018